Pharmaceutical - Pharmaceutical, Men's Health

Filter

Popular Filters

1 to 25 of 59 results

Trimel and Endo agree on Natesto manufacturing and marketing collaboration

Trimel and Endo agree on Natesto manufacturing and marketing collaboration

24-11-2014

Trimel Biopharma, a subsidiary of Canada's Trimel Pharmaceuticals Corp, has signed an agreement with…

CanadaEndoLicensingMarkets & MarketingMen's HealthPharmaceuticalTrimel PharmaceuticalsUSA

Forendo licenses fispemifene to Apricus in USA

20-10-2014

Finland-based Forendo Pharma, a Swedish firm Karolinska Development portfolio company, has entered into…

Apricus BiosciencesfispemifeneForendo PharmaGenito-urinaryKarolinska DevelopmentLicensingMen's HealthPharmaceuticalUSA

Endo’s buy of struggling Auxilium for $2.6 billion analysed by GlobalData

12-10-2014

Endo International’s $2.6 billion purchase of Auxilium Pharmaceuticals (The Pharma Letter October 9)…

Auxilium PharmaceuticalsEndo InternationalMen's HealthMergers & AcquisitionsPharmaceuticalRare diseasesTestimTestopelXiaflex

Highlights from EMA Pharmacovigilance October meeting

10-10-2014

At its October meeting, the European Medicines Agency’ Pharmacovigilance Risk Assessment Committee…

Ariad PharmaceuticalsEuropeIclusigMen's HealthNeurologicalOncologyPharmaceuticalRegulationTestosteronevalproate

Auxilium Pharma succumbs to higher, $2.6 billion, offer from Endo

Auxilium Pharma succumbs to higher, $2.6 billion, offer from Endo

09-10-2014

Having previously rejected a $28.10 a share takeover offer from Ireland-headquartered Endo International,…

Auxilium PharmaceuticalsEndo InternationalIrelandMen's HealthMergers & AcquisitionsPharmaceuticalQLTUSA

Auxilium Pharma rejects Endo acquisition in favor of QLT deal

Auxilium Pharma rejects Endo acquisition in favor of QLT deal

22-09-2014

Auxilium Pharmaceuticals’ board of directors, after review of the unsolicited $2.2 billion takeover…

AuxiliumCanadaEndo InternationalMen's HealthMergers & AcquisitionsPharmaceuticalQLTUSA

Vivus and Auxilium’s Stendra ED drug approved as “on-demand” treatment in USA

Vivus and Auxilium’s Stendra ED drug approved as “on-demand” treatment in USA

19-09-2014

The US Food and Drug Administration has approved a supplemental New Drug Application for Stendra (avanafil),…

Auxilium PharmaceuticalsMen's HealthPharmaceuticalRegulationStendraUSAVivus

First domestic-made erectile dysfunction drug debuts in China

19-09-2014

A Chinese pharmaceutical company on Thursday launched the country's first domestic-made erectile dysfunction…

Bai Yun Shan PharmaceuticalChinaJingeMarkets & MarketingMen's HealthPharmaceutical

FDA calls for tighter controls over testosterone replacement therapies

FDA calls for tighter controls over testosterone replacement therapies

19-09-2014

An advisory panel of the US Food and Drug Administration has voted to tighten use of testosterone replacement…

AndrogensAndrologyClarus TherapeuticsEndocrine systemMen's HealthPharmaceuticalRegulationRextoroTestosterone replacementUSA

Plethora signs licensing agreement with Recordati for premature ejaculation drug

Plethora signs licensing agreement with Recordati for premature ejaculation drug

16-09-2014

Urological specialist Plethora Solutions has signed a licensing agreement with international pharma group…

EuropeLicensingMen's HealthPharmaceuticalPlethoraPSD502Recordati

FDA adding general warning to testosterone products potential for venous blood clots

FDA adding general warning to testosterone products potential for venous blood clots

22-06-2014

The US Food and Drug Administration is requiring manufacturers to include a general warning in the drug…

Men's HealthPharmaceuticalRegulationTestosteroneUSA

Brintellix superior to escitalopram in improving sexual functioning for MDD patients

Brintellix superior to escitalopram in improving sexual functioning for MDD patients

17-06-2014

Danish CSN drug specialist Lundbeck has presented results about sexual functioning from a head-to-head…

BrintellixEscitalopram OxalateLundbeckMen's HealthNeurologicalPharmaceuticalResearch

Sanofi and Lilly announce licensing agreement for Cialis OTC

Sanofi and Lilly announce licensing agreement for Cialis OTC

28-05-2014

French drug major Sanofi and US drug major Eli Lilly have agreed to pursue regulatory approval of non-prescription…

CialisEli LillyEli Lilly and CompanyEuropean Medicines AgencyFranceLicensingMen's HealthPDE5 inhibitorsPharmaceuticalSanofiTreatment of men with erectile dysfunctionVincent Warnery

Pharmacovigilance Risk Assessment Committee April meeting highlights

Pharmacovigilance Risk Assessment Committee April meeting highlights

11-04-2014

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) gave a recommendation…

Cardio-vascularEuropeMen's HealthNeurologicalPharmaceuticalRegulationRespiratory and Pulmonary

Pfizer tackles Torrent over generic Viagra

Pfizer tackles Torrent over generic Viagra

19-03-2014

US pharma giant Pfizer is taking legal action against Indian drugmaker Torrent Pharmaceuticals to stop…

GenericsIndiaLegalMen's HealthPfizerPharmaceuticalTorrent PharmaceuticalsUSAViagra

Endo’s testosterone replacement Aveed gets FDA approval

Endo’s testosterone replacement Aveed gets FDA approval

06-03-2014

Endo International says its operating company Endo Pharmaceuticals has received US Food and Drug Administration…

AveedEndo PharmaceuticalsMen's HealthNorth AmericaPharmaceuticalRegulationUSA

Recordati gains certain rights to Apricus’ Vitaros

10-02-2014

Italian drugmaker Recordati has signed an exclusive license agreement with the USA’s Apricus Biosciences…

Apricus BioscienceEastern EuropeLicensingMen's HealthPharmaceuticalRecordatiRest of the WorldTurkeyVitaros

FDA investigating risk of stroke, heart attack and death with testosterone products

FDA investigating risk of stroke, heart attack and death with testosterone products

03-02-2014

The US Food and Drug Administration said on Friday that it is investigating the risk of stroke, heart…

AbbVieActavisAndrodermAndroGelAxironEli LillyMen's HealthNorth AmericaPharmaceuticalRegulationResearchTestosteroneUSA

Ampio Pharma takes spin-out route on failure to find Zertane partner

Ampio Pharma takes spin-out route on failure to find Zertane partner

16-12-2013

US drug developer Ampio Pharmaceuticals announced that it has spun off its sexual dysfunction business…

Ampio PharmaceuticalsAmpionInflammatory diseasesMen's HealthMergers & AcquisitionsPharmaceuticalProductionVyrix PharmaceuticalsZertane

Apricus expands Vitaros deal with Novartis unit

Apricus expands Vitaros deal with Novartis unit

16-12-2013

USA-based Apricus Biosciences has expanded its exclusive license agreement with Hexal AG, an affiliate…

Apricus BioscienceEuropeLicensingMen's HealthNovartisPharmaceuticalSandozVitaros

Sanofi to commercialize Vivus ED drug in Africa, Middle East, Turkey and CIS/Russia

Sanofi to commercialize Vivus ED drug in Africa, Middle East, Turkey and CIS/Russia

12-12-2013

US drugmaker Vivus has entered into a license and commercialization agreement with French pharma major…

avanafilEastern EuropeLicensingMarkets & MarketingMen's HealthPharmaceuticalRest of the WorldSanofiVivus

Increase in awareness of hypogonadism will drive testosterone replacement therapy market

11-12-2013

The testosterone replacement therapy (TRT) market has been forecast to reach a value of $5.1 billion…

GlobalMarkets & MarketingMen's HealthPharmaceutical

US FDA approves first drug treatment for Peyronie’s disease

US FDA approves first drug treatment for Peyronie’s disease

07-12-2013

The US Food and Drug Administration has approved a new use for US company Auxilium Pharmaceuticals Xiaflex…

Auxilium PharmaceuticalsMen's HealthNorth AmericaPharmaceuticalRegulationXiaflex

Majorelle to market Apricus’ ED product in France, Monaco and certain African countries

13-11-2013

USA-based Apricus Biosciences has signed an exclusive license agreement with Laboratoires Majorelle,…

Apricus BioscienceEuropeLaboratoires MajorelleLicensingMen's HealthPharmaceuticalRest of the WorldVitaros

1 to 25 of 59 results

Back to top